Whalesbook
Recent market performance highlights investors balancing near-term geopolitical risks against strong order books and growth outlooks. The companies' capacity to absorb price target cuts while showing gains indicates investor confidence in their strategies and core business strength amid global uncertainties.
Core Catalysts and Market Reaction
Aurobindo Pharma has triggered a significant upward breakout, confirmed by momentum indicators like DMI and MACD, alongside an RSI above 60, suggesting renewed bullish sentiment. Trading around ₹1280-₹1260, it aims for a ₹1390 target with a ₹1235 stop loss. Meanwhile, Infosys exhibits a bullish divergence on its RSI, hinting at a potential reversal from recent lows, with the MACD confirming improving momentum. The recommended buy range is ₹1270-₹1240, targeting ₹1375 and a ₹1175 stop loss. Larsen & Toubro (L&T) shows signs of an oversold bounce, with RSI positive divergence and an oversold MACD indicating possible trend exhaustion. A buy range of ₹3400-₹3350 is suggested, with a ₹3250 stop loss and a ₹3600 target. L&T recently traded around ₹3435 as of March 20, 2026, reflecting a notable recovery from prior declines.
Valuation Snapshot
Aurobindo Pharma's Price-to-Earnings (P/E) ratio is around 21.35 as of March 2026, placing it below the broader Indian pharmaceutical sector's average P/E, which ranges from 33.3 to 41.16. Its market capitalization stands at approximately ₹74,500 Cr. Infosys has a P/E ratio of 17.05 to 18.51 as of March 2026, below its historical 3-5 year average P/E, suggesting a potentially attractive valuation compared to its historical average. Its market cap is around ₹518,386 Cr. Larsen & Toubro's P/E ratio varies, reported between 25.48 and 31.03 in March 2026, is near the infrastructure sector's average of 28.2x. However, its P/E is higher than some peers like Adani Ports (28.1x-28.59x) but lower than others like Siemens (65.11x). L&T's market cap is large, around ₹4.72 lakh Cr.
Analyst Sentiment
Analyst sentiment for Aurobindo Pharma is largely positive, with a 'Buy' consensus. Of 26 analysts, the majority recommend buying, with a few suggesting selling. Average price targets are around ₹1,346.23, suggesting upside potential. PhillipCapital and JM Financial have issued price targets of ₹1,540 and ₹1,610 respectively. For Infosys, the analyst consensus is mostly 'Hold'. Out of 5 analysts, 80% recommend holding, while 20% advise a strong sell. Price targets are in the $17-$18 range. Despite this, several firms like TD Cowen and BMO Capital have raised their price targets. Larsen & Toubro, however, has a 'Strong Buy' consensus from 5 analysts, with average price targets around ₹4,703.00 indicating significant upside. This positive sentiment continues even as some brokerages like Jefferies and Motilal Oswal have trimmed their price targets.
Key Risks and Challenges
Despite a positive breakout, Aurobindo Pharma's valuation, while below industry averages, does not offer deep discounts. Investors must monitor its ability to integrate its Lannett acquisition effectively, which aims to strengthen its US presence and product portfolio. For Infosys, the outlook is cautious. The stock has experienced a 29.4% decline over the past year and hit a 52-week low, with its Relative Strength Index (RSI) suggesting oversold conditions. The IT sector itself is facing challenges, with revenue declines reported. The widespread 'Hold' consensus among analysts and a number of 'Sell' ratings suggest that immediate recovery might be difficult without broader sector improvements. Larsen & Toubro, despite its 'Strong Buy' consensus and robust order book, faces significant risks from rising geopolitical tensions in West Asia. These conflicts are driving up key input costs, including bitumen (up 20-50% in March 2026), steel (up 18-25%), and fuel. This could lead to 5-8% cost increases and project delays for infrastructure development, potentially squeezing margins for L&T and other large players. Furthermore, L&T's stock has been trading below its key moving averages, signaling short-term technical weakness despite recent bounces.
Future Outlook
For Aurobindo Pharma, the strategic acquisition of Lannett provides a clear path to expand its global reach and broaden its product range, with analysts projecting an upside of over 20%. Infosys's future depends on navigating the challenging IT sector environment; while some analysts have raised price targets, the overall consensus remains cautious, with an average target implying a near 30% upside. The IT major's performance in the BFSI sector has been solid, but overall revenue has seen a decline, requiring close attention to operational efficiency and future guidance, particularly for fiscal year 2027 where acceleration is expected. Larsen & Toubro's long-term prospects remain strong, supported by a significant order book, but near-term challenges from rising input costs due to geopolitical factors could temper its growth outlook. Analyst price targets suggest considerable upside, showing confidence in its ability to manage these challenges, with a focus on its upcoming strategy unveiling in May 2026 to clarify order flow and margin management.